Helix BioPharma (TSE:HBP) Shares Cross Below Two Hundred Day Moving Average – Time to Sell?

Helix BioPharma Corp. (TSE:HBP)’s stock price passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of C$2.12 and traded as low as C$1.80. Helix BioPharma shares last traded at C$1.99, with a volume of 1,619 shares traded.

Helix BioPharma Stock Performance

The firm’s 50 day simple moving average is C$2.04 and its 200 day simple moving average is C$2.12. The firm has a market capitalization of C$151.99 million, a price-to-earnings ratio of -28.43 and a beta of 0.18. The company has a debt-to-equity ratio of 2.19, a quick ratio of 1.04 and a current ratio of 0.23.

Helix BioPharma Company Profile

Helix BioPharma is an oncology company that innovates from strength to bring near-term solutions for today’s hardest-to-treat cancers. The Company’s pipeline is led by Tumor Defense Breaker¿ L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy and augment the effectiveness of today’s front-running anti-cancer treatments. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with Helix’s next-generation bi-specific antibody-drug conjugates (ADCs), currently in discovery.